Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RiCOTTA study in staphylococcal prosthetic joint infection
2022-501620-26-00Phase 4Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2023
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of rifampicin, clindamycin, doxycycline, minocycline, moxifloxacin and 3 more in periprosthetic joint infection (PJI) and Staphylococcal periprosthetic joint infection (SPJI) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Treatment success at 15 months after DAIR. Planned start Feb 2023; status: authorised.
02
Drugs
rifampicinclindamycindoxycyclineminocyclinemoxifloxacin
03
Conditions
periprosthetic joint infection (PJI)Staphylococcal periprosthetic joint infection (SPJI)
Beyond the preview
Go deeper on 2022-501620-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501620-26-00.